Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01554371 · ClinicalTrials.gov registry record · Phase 1
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01554371 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 44 participants.
The verdict
NCT01554371, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. This study will look at what effects, good and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved by the FDA for breast cancer that has spread to other parts of the body. Cyclophosphamide has been approved for different types of cancers (including breast cancer). However, the combination of eribulin and cyclophosphamide is considered experimental; that means this combination has not been approved by the FDA. The funding for this study is provided by Eisai Inc., the maker of eribulin.
Interventions
- DRUG Cyclophosphamide
- DRUG Eribulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-03-27 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01554371
The ClinicalTrials.gov registry entry for NCT01554371 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT01554371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01554371 about?
NCT01554371 is a clinical study titled "Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies". The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. This study will look at what effects, good and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved by the FDA for breast canc...
What is the current status of trial NCT01554371?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2012-03-27. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT01554371?
The interventions under investigation include: Cyclophosphamide (DRUG), Eribulin (DRUG).
Who is sponsoring clinical trial NCT01554371?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.